HYUNDAI BIOSCIENCE CO., LTD. Logo

HYUNDAI BIOSCIENCE CO., LTD.

Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.

048410 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경상북도 김천시 아포읍 아포공단길 106, 김천시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HYUNDAI BIOSCIENCE CO., LTD. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapeutics through its advanced drug delivery systems (DDS) and bio-fusion technologies. The company's core mission is to create safer and more effective treatments for critical diseases. Its development pipeline features CP-COV03, a broad-spectrum antiviral drug candidate designed to treat viral infections by enhancing cellular autophagy, and Polytaxel, a next-generation anticancer agent engineered to minimize toxicity and patient discomfort. The company's proprietary technology platform, utilizing organic-inorganic hybrid materials, also underpins its commercialized bio-functional products. Through strategic partnerships with global universities and companies, Hyundai Bioscience aims to contribute significantly to human health and life extension.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HYUNDAI BIOSCIENCE CO., LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 113.3 KB
2025-09-16 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 2/3상 …
Korean 13.7 KB
2025-09-08 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인)
Korean 12.7 KB

Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
NATURECELL CO.,LTD. Logo
Biotech company developing stem cell therapies, food, beverages, and cosmetics.
South Korea 007390
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.